Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspire Biopharma Holdings, Inc. filings document the company’s public-company reporting, securities offerings, shareholder votes, governance matters and capital structure. Proxy materials cover stockholder approval matters involving warrant issuances, warrant adjustments, Nasdaq Rule 5635(d) compliance and reverse stock split authority.
Material-event reports and amendments describe securities purchase agreements, Series A convertible preferred stock, registration rights, financing tranches and corrections to prior disclosures. Registration statement filings provide offering disclosures, risk factors, operating and financial information, and security-structure details for the company’s common stock and related securities.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.
The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.
Aspire Biopharma Holdings, Inc. has signed a non-binding Letter of Intent to acquire Dura Driver Control Systems (DCS), a tier-one automotive and industrial systems supplier. Aspire expects to buy 100% of DCS for $30 million in cash, subject to due diligence and a definitive agreement.
For the fiscal year ended December 31, 2025 (unaudited), DCS generated more than $200 million in revenue, over $17 million in net income and over $22 million in Adjusted EBITDA. DCS supplies mechatronic actuators, human‑machine interfaces, industrial cables and control systems, backed by more than 310 patents and 11 manufacturing facilities worldwide.
The contemplated acquisition would diversify Aspire beyond biopharmaceutical drug delivery technology into a higher‑revenue industrial and automotive platform. The company cautions there is no assurance a definitive agreement will be finalized or that the transaction will close, and any deal would be subject to customary conditions and audited financials.
Aspire Biopharma Holdings, Inc. entered into a non-binding letter of intent to acquire 100% of the Driver Controls Systems business unit of Firefish Topco, LLC for an enterprise value of $30.0 million on a cash-free, debt-free basis, payable in cash at closing.
The LOI includes reciprocal break-up fees of $3.5 million under specified failure-to-close or bad-faith scenarios, as well as a 30-day no-shop period for the sellers, subject to possible extension. Most LOI terms are non-binding, and completion depends on negotiating and signing a definitive purchase agreement and satisfying closing conditions. Following a completed acquisition, the company plans to engage Lakewood & Company, LLC to provide management services for DCS, subject to a separate definitive management agreement.
Aspire Biopharma Holdings, Inc. is registering up to 159,090,906 shares of common stock for resale by existing investors, issuable upon conversion of its Series A Convertible Preferred Stock. These selling shareholders, not the company, will receive any proceeds from share sales.
The Preferred Stock supports up to $20 million of financing, with a first tranche of $11 million already funded on February 6, 2026 and a potential second tranche of up to $10 million contingent on conditions including effectiveness of this registration. The preferred converts at a variable price with a $0.264 per-share floor and a 4.99%–9.99% beneficial ownership cap, limiting how much common stock any holder can own after conversion.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technology. Its lead high-dose sublingual aspirin product has completed a positive pharmacokinetic clinical study showing faster blood availability and stronger platelet inhibition than standard oral aspirin, with a 505(b)(2) NDA submission targeted for 2026. The company is also advancing sublingual melatonin, vitamin, caffeine and other formulations, including its “Buzz Bomb” caffeine supplement line.
Aspire Biopharma Holdings, Inc. files an amended annual report to add its independent auditor’s report and related certifications, with no other changes to the original Form 10-K for the year ended December 31, 2025.
The company describes itself as an early-stage biopharmaceutical developer of patent-pending sublingual drug delivery technologies, led by a high‑dose sublingual aspirin program progressing toward a planned 505(b)(2) NDA submission. As of March 27, 2026, Aspire had 5,024,124 shares of common stock outstanding, and the aggregate market value of voting stock held by non‑affiliates was about $17.4 million as of December 31, 2025.
Aspire Biopharma Holdings, Inc. filed its annual report outlining its transformation from SPAC PowerUp into a commercial‑stage biopharma platform focused on novel sublingual drug delivery, led by a high‑dose aspirin program for suspected acute myocardial infarction and multiple supplement and therapeutic candidates.
The company reports a reverse recapitalization valuing Aspire Biopharma, Inc. at $350 million, multiple convertible financings and a $100 million equity line of credit to fund development. As of March 27, 2026, there were 5,024,124 shares of common stock outstanding. Aspire highlights positive pharmacokinetic data from a 2025 sublingual aspirin trial supporting a planned 505(b)(2) NDA in 2026 and early commercial rollout of its Buzz Bomb caffeine supplement.
Aspire Biopharma Holdings, Inc. is calling a special stockholder meeting on April 10, 2026 to approve several capital structure and financing actions. The Board seeks authority for a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-500, to help maintain Nasdaq listing and potentially support liquidity.
Stockholders are also asked to approve the issuance of common shares upon conversion of newly issued Series A Convertible Preferred Stock, including amounts above 19.99% of common shares outstanding on February 6, 2026, and to approve a floor conversion price set at 20% of the Nasdaq-defined Minimum Price. A separate proposal would approve issuing 20% or more of outstanding common stock under a $100,000,000 equity line (ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd., and another would increase authorized common shares from 490,000,000 to 700,000,000. As of February 11, 2026, 5,024,142 common shares were outstanding.
Aspire Biopharma Holdings, Inc. has filed an S-1 to register the resale of up to 159,090,906 shares of common stock issuable upon conversion of its Series A Convertible Preferred Stock. These shares may be sold from time to time by selling shareholders, and the company will not receive proceeds from these resales.
The Preferred Stock supports up to $20,000,000 of financing, with a first tranche of $11,000,000 already funded, partly via debt conversion, and a potential second tranche of up to $10,000,000 tied to this registration’s effectiveness. Conversion is priced off market trading levels with a floor price of $0.264 per share and is limited by a 4.99% beneficial ownership cap, adjustable to 9.99% with notice, to restrict any single investor’s stake.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technologies, led by a high-dose sublingual aspirin program that has completed a positive pharmacokinetic trial and is being advanced toward a planned 505(b)(2) NDA submission targeted for late 2026. The company is also commercializing “Buzz Bomb” caffeine supplements and developing additional sublingual products, including melatonin, vitamins, nicotine and other drug candidates, while managing a complex capital structure that includes past convertible notes, an equity line of credit and reverse recapitalization through a SPAC merger.
Aspire Biopharma Holdings, Inc. is asking stockholders to approve several major capital and governance actions at a special meeting on April 10, 2026. As of the February 11, 2026 record date, there were 5,024,142 shares of common stock outstanding. The company seeks authority for a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-500 to help maintain Nasdaq listing and potentially improve trading liquidity. It is also requesting approval, under Nasdaq Listing Rule 5635(d), to issue common shares upon conversion of Series A Convertible Preferred Stock above the 19.99% ownership threshold, and to issue 20% or more of its common stock under a $100,000,000 equity line of credit with Arena Business Solutions Global SPC II, Ltd. Another proposal would increase authorized common stock from 490,000,000 to 700,000,000 shares, significantly expanding capacity for future issuances. A final proposal would allow adjournment of the meeting to solicit additional proxies if support for these items is initially insufficient. The board recommends voting “FOR” all proposals.